Clinical Trial Highlights

• Does Aspirin's Ability to Improve CRC Prognosis Depend on PIK3CA Mutation Status?
• New Analysis of CRYSTAL Results Supports Patient Selection According to RAS Mutation Status to Maximize Benefit from CET Therapy
• MM-398 Plus 5-FU and LV Extend OS and PFS in mPAC
• MPACT Trial: SPARC Not Predictive or Prognostic in Pancreatic Cancer
• Cetuximab Fails to Extend OS in Locally Advanced Esophageal Cancer
• High Fatty Acids and Low Fiber Intake is Associated with CRC
• RAINBOW Study Shows Significant Benefits in OS and PFS in Western Patients with Gastric Cancer
• No Benefit to Adding Oxaliplatin to Capecitabine in Locally Advanced Rectal Adenocarcinoma
• Active Maintenance Therapy Prolongs TFS and PFS in CRC
• KRAS Mutations Predictive of Recurrence in Colon Cancer
• Impact of First-Line Therapy on Selection of Second-Line Therapy in FIRE-3 Trial
• Outcomes Similar with BEV or CET Added to Induction CT for mCRC
• Regorafenib Improves OS in Asian Patients with mCRC after Previous Failure with Standard Therapy